Beetroot Juice to Prevent Kidney Injury From Contrast Dye in Heart Patients
Tests beetroot juice against usual care to prevent kidney injury after heart catheterization.
Plain-language title generated from the registry record
Registry title: Supplementation With Beetroot Juice to Prevent Contrast Associated Nephropathy During Hospitalization for Acute Coronary Syndrome Without ST Elevation
Key facts
- Where
- Cartagena, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults hospitalized with a heart attack-type chest condition (acute coronary syndrome without persistent ST elevation) who are at higher risk of kidney injury from contrast dye during heart catheterization.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute coronary syndrome without persistent ST segment elevation, with invasive management advised by current guidelines. At least moderate or high risk of kidney injury from iodinated contrast (Mehran score of 6 or more, without counting contrast volume).
- Earlier treatment
- Cannot join if a coronary stent or balloon procedure (PCI) was already done before inclusion, or if intravenous nitroglycerin was given for more than 1 hour before inclusion.
Main reasons for not taking part
- Known allergy to beetroot
- Pregnant
- On dialysis or predialysis
- ACS with persistent ST segment elevation, shock, or need for inotrope drugs
- Serious illness expected to limit life to less than 1 year, or unable to take food by mouth
Read by machine on 9 November 2026.
Where in Spain
- Hospital Universitario Santa LucíaCartagena, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital General Universitario Santa Lucia
- Trial code
- NCT06695429
- Record updated
- 18 May 2025
- Original description
The goal of this study is to compare the possible beneficial effect of beetroot juice supplementation versus the usual management during hospitalization to prevent contrast-induced nephropathy after cardiac catheterizations.Read full original descriptionShow less
Suplementación Con Zumo de REmolacha Para Prevenir la Nefropatía Asociada a Contraste Durante la hospitalización Por Síndrome Coronario Agudo Sin elevación Del ST
The goal of this study is to compare the possible beneficial effect of beetroot juice supplementation versus the usual management during hospitalization to prevent contrast-induced nephropathy after cardiac catheterizations.
The study includes patients diagnosed with non-ST elevation acute coronary syndrome with a possible indication for catheterism and high risk of kidney injury related to iodinated contrast.
The intervention group will drink 500 mL (2 glasses daily, at breakfast and dinner) of beetroot juice added to the usual diet for 7 days or until hospital discharge and will receive the recommendation to maintain a diet rich in inorganic nitrates. The control group will receive the usual diet and recommendations. In both cases, other therapies will be prescribed to prevent contrast-induced nephropathy (hydration and statins) if there is no contraindication.
Our hypothesis is that a compound present in beetroot juice, inorganic nitrates, can prevent the deterioration of kidney function related to contrast due to its vasodilatory effect, in addition to improving the subsequent prognosis of coronary heart disease due to its anti-inflammatory and antiproliferative effects, protector of the endothelium and inhibitor of platelet aggregation. Beetroot juice could also be beneficial in this context due to the antioxidant effect of the betalains it contains.
Inclusion: Diagnosis of Acute Coronary Syndrome without persistent ST segment elevation, with recommendation for invasive management according to the actual Clinical practice guidelines; At least moderate or high risk of nephropathy associated with iodinated contrast (Mehran score (without including contrast volume) ≥ 6).
Exclusion: Patients receiving intravenous nitroglycerin for > 1 hour before inclusion; Known hypersensitivity to beetroot or any of its allergens; Serious illnesses (not related to ACS or kidney failure), which limits their life expectancy to a period predictably less than 1 year; <18 years old or without capacity to give consent; Refusal to participate in the study; Pregnant; Inability to take food orally; On dialysis or predialysis at the time of inclusion; ACS with persistent ST segment elevation before inclusion; Shock or inotrope dependence at the time of inclusion; PCI already performed before inclusion.